Decompensated Aortic Stenosis: Time to TAVR Matters

Aortic stenosis prevalence is expected to increase in the coming years mainly driven by increased life expectancy. Patients will often find out when experiencing resting dyspnea, syncope, or signs and symptoms of acute deterioration, such as cardiac failure, referred to as acute decompensated aortic stenosis (ADAS). As we all know, optimal medical treatment in these cases is limited, with poor prognosis at hospital discharge, 30 days and one year. 

This analysis included 276 patients with ADAS; 150 received TAVR within ≤22 days after hospitalization and the rest, beyond this period. 

The primary outcome was hospitalization for cardiac failure or all-cause mortality.

The groups were comparable: mean patient age 84, 63% men, 53% hypertensive, 35% had coronary artery disease, 5% had PCI within 90 days prior TAVR, 26% had diabetes, 58% kidney function deterioration, 23% COPD and estimated glomerular filtration rate (eGFR) was 55 ml/min. Mean EuroSCORE was 6,5% and 3% required cardiopulmonary support.

Mean ejection fraction was 55%; 15% presented ejection fraction <30%. There were no differences in aortic valve area, gradients, velocity or presence of mitral or tricuspid regurgitation. 40% of patients presented stage >2 deterioration. 

Read also: EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients.

Mean time to TAVR was 14 days in ≤22 day patients and 33 days in the >22 group. 

There were no differences in valve type or hospital evolution. 

Patients were followed up to 4,6 (3,6–5,7) years. The primary outcome was seen in 58% of patients. Time to TAVR (for every 5-day delay) was significantly associated to the primary outcome (hazard ratio [HR], 1,09 [CI 95%, 1,03–1,14]; P=0,002). Also, >22 days to TAVR was associated to higher risk of adverse events (HR 1,48 [CI 95%, 1,09–2,03]; P=0,013).

Read also: Transcatheter Tricuspid Valve Replacement: 1-Year Outcomes.

The was a significant link between the primary outcome and the presence of syncope, COPD, stroke, stage >2 and the need for cardiopulmonary support.

Conclusion

In patients with acute decompensated aortic stenosis, a longer wait to TAVR was associated to increased risk of events at mid-term. 

Original Title: Shorter Time to Transcatheter Aortic Valve Implantation Is Associated With Improved Outcomes in Acute Decompensated Aortic Stenosis.

Reference: Michael McKenna, et al. Circ Cardiovasc Interv. 2025;18:e014915. DOI: 10.1161/CIRCINTERVENTIONS.124.014915.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

TAVR in Women

Severe aortic stenosis (AS) in women shows distinct features, compared to men, with lower prevalence of heart disease, among other differences. However, women have...

Early and Late Readmission after Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAC) represents an effective alternative for patients with atrial fibrillation and anticoagulation contraindication. This study looked at incidence, predictors...

Impact of Tricuspid Regurgitation in Mitral V-in-V

The coexistence of mitral regurgitation (MR) and tricuspid regurgitation (TR) presents a therapeutic dilemma. While surgery is often the preferred course of action, it...

Long-Term Outcomes of PFO Closure

Patent foramen ovale (PFO) is a recognized cause of cryptogenic stroke, and its closure via percutaneous treatment has been shown to be effective compared...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Women

Severe aortic stenosis (AS) in women shows distinct features, compared to men, with lower prevalence of heart disease, among other differences. However, women have...

Early and Late Readmission after Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAC) represents an effective alternative for patients with atrial fibrillation and anticoagulation contraindication. This study looked at incidence, predictors...

OCT Assessment of Bioresorbable Scaffold Performance across Different Types of Plaque

The development of bioresorbable magnesium scaffolds (RMS) has generated significant expectation in the field of percutaneous coronary intervention, especially because it could potentially restore...